MMP2 and AL amyloidosis: Using an MMP-2 specific quenched fluorescent substrate, we demonstrated that ML104 significantly reduced MMP-2 activity in the multiple myeloma-bone microenvironment compared to either the control or zoledronate groups (Figure 7A).